HAL Appoints Dr. Nikhil Agarwal as Independent Director Effective 9 September 2026
NiveshIQ
NSE: AGARWALEYE · Healthcare
Dr. Agarwal's Health Care Ltd.
₹508.40▲ ₹0.05 (+0.01%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on AGARWALEYE. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Dr. Agarwal's Health Care Ltd.
Dr. Agarwal's Health Care Limited operates a vertically integrated eye care chain that includes hospitals, opticals, pharmacies, and diagnostic device manufacturing, generating ₹2,207 Cr in revenue and ₹148 Cr net income in FY27. The company’s core revenue drivers are cataract and refractive surgeries, with femto cataract procedures and retinal surgeries contributing over 40% of surgical income, while opticals and contact lenses account for 25% of total sales. Recent Q2 FY27 results showed a 12% YoY revenue growth and a 15% increase in operating margin, reflecting strong demand for its high‑tech surgical services. The firm is expanding its presence in Delhi NCR, opening 12 new centers by 2028, and has secured a partnership to distribute its optical biometers in Southeast Asia, enhancing it
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,328 Cr +30.40% | ₹1,711 Cr +28.90% | ₹2,080 Cr +21.60% |
| EBITDA Margin | 28.89% | 26.71% | 29.52% |
| Net Profit | ₹83.06 Cr -19.40% | ₹110.00 Cr +32.40% | ₹166.81 Cr +51.60% |
| EPS | – | ₹1.75 | ₹4.21 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Dr. Agarwal's Health Care Bull Case vs Bear Case for 2026
Dr Agarwal's Health Care Q2 Results FY27: Date, View
🔒
+ 3 more stories about Dr. Agarwal's Health Care Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹614 Cr, PAT ₹55 Cr, EPS ₹1.43, EBITDA margin 28.8%. Growth context: revenue QoQ +8.8%, PAT QoQ +13.1%. Street verdict: strong beat, revenue surprise +3.7%, PAT surprise +57.8%.
Recent corporate activity highlights product launches, approvals, and therapy-mix improvement and new capacity addition ...
FY26 (last completed FY): revenue ₹2, 080 Cr, PAT ₹167 Cr, EBITDA margin 29.5%, EPS ₹4.21. Year-on-year: revenue YoY +21...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for AGARWALEYE
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track AGARWALEYE alongside your other holdings
Unlock full AGARWALEYE research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Dr. Agarwal's Health Care Ltd.?
NiveshIQ detects active intelligence signals for Dr. Agarwal's Health Care Ltd. (AGARWALEYE) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Dr. Agarwal's Health Care Ltd.?
Dr. Agarwal's Health Care Ltd. operates in the Healthcare sector with a market capitalisation of ₹1,437,403.5L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.